Downtrend on the daily chart: below its 50-day average · SuperTrend down since Sep 8 · below the Ichimoku cloud · RSI 31 · MACD above its signal · 3% above its 52-week low
| 16.77 | 52-week high | +115.00% |
| 14.68 | Previous month high | +88.21% |
| 8.50 | Previous week high | +8.97% |
| 8.14 | R3 (classic) | +4.40% |
| 8.05 | Previous month low | +3.21% |
| 8.01 | R2 (classic) | +2.65% |
| 7.91 | R1 (classic) | +1.45% |
| 7.87 | Previous day high | +0.90% |
| 7.80 | Price now | |
| 7.78 | Pivot | −0.30% |
| 7.68 | S1 (classic) | −1.50% |
| 7.64 | Previous day low | −2.05% |
| 7.63 | Previous week low | −2.18% |
| 7.55 | S2 (classic) | −3.25% |
| 7.54 | 52-week low | −3.33% |
| 7.45 | S3 (classic) | −4.44% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $201.4K | 0.00% | 14.97K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RNA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
TimeframesThe daily and weekly trends are down; the hourly is steadying, a bounce inside them.
under a flat 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 19, 2026 | Hughes Steven GeorgeOfficer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Apr 19, 2026 | Gallagher Kathleen PChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 102.5K | — |
| Apr 19, 2026 | Younis HusamOfficer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Apr 19, 2026 | Hoyos Rocio MartinOfficer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Apr 19, 2026 | Kenney StephanieOfficer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Apr 19, 2026 | Winslow Brendan RChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Buy / hold / sell counts